The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Open accessAbstract
Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.Methods In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.Findings Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.Interpretation Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Initial results demonstrated a 31% objective response rate and 69% demonstrated at least 12 weeks of stable disease [78].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [78]
In the citing paper
“The Checkmate-142 phase II study demonstrated the effectiveness of nivolumab in previously treated MSI-H mCRC patients [84].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Upon examining the subgroup analysis of this study, it was observed that patients without RAS or BRAF mutations achieved a 41% objective response rate with nivolumab. In comparison, the rate was 27% in RAS mutant patients.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53,54,55,56].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Nivolumab, an anti-PD1 monoclonal antibody (moAb), has been utilized since 1 August 2017, for MSI-H/dMMR mCRC, as evidenced by the CheckMate 142 study [54].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“The CHECKMATE 142 study reported that Nivolumab could provide a durable response in patients with dMMR/MSI-H metastatic colorectal cancer, proposing Nivolumab as a new treatment option in these patients [117].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [117]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cited by
Sorted by citations
Items 501–600 of 1,005
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook
Ng, C. K. Y., Costanzo, G. G. D., Terracciano, L., & Piscuoglio, S. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00078 · Cited by 57
Ohmoto, A., Yachida, S., & Morizane, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030561 · Cited by 58
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Microbiota and Colorectal Cancer: From Gut to Bedside
Silva, M. G., Brunner, V., & Tschurtschenthaler, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760280 · Cited by 61
KRAS: A Druggable Target in Colon Cancer Patients
Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 57
de Malet, A., Antoni, G., Collins, M., Soularue, É., Marthey, L., Vaysse, T., Coutzac, C., Chaput, N., Mateus, C., Robert, C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.006 · Cited by 58
Precision medicine for metastatic colorectal cancer: an evolving era
Güler, İ., Aşkan, G., Klostergaard, J., & Şahin, İ. H. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1663174 · Cited by 56
Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors
Grywalska, E., Sobstyl, M., Putowski, L. T., & Roliński, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194705 · Cited by 56
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 57
Challenges in assessing solid tumor responses to immunotherapy
Chai, L. F., Prince, E. A., Pillarisetty, V. G., & Katz, S. C. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0155-1 · Cited by 56
Zoetemelk, M., Ramzy, G. M., Rausch, M., & Nowak-Sliwinska, P. M. (2020) · Molecules · doi:10.3390/molecules25112614 · Cited by 57
Immune profiling of pediatric solid tumors
Terry, R. L., Meyran, D., Ziegler, D. S., Haber, M., Ekert, P. G., Trapani, J. A., & Neeson, P. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137181 · Cited by 54
Min, A. K. T., Mimura, K., Nakajima, S., Okayama, H., Saito, K., Sakamoto, W., Fujita, S., Endo, H., Saito, M., Saze, Z., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02676-8 · Cited by 57
The Tumor Microenvironment of Colorectal Cancer Metastases: Opportunities in Cancer Immunotherapy
Kamal, Y., Schmit, S. L., Frost, H. R., & Amos, C. I. (2020) · Immunotherapy · doi:10.2217/imt-2020-0026 · Cited by 56
Microsatellite Instability and Metastatic Colorectal Cancer – A Clinical Perspective
Büchler, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888181 · Cited by 55
Emiloju, O. E., & Sinicrope, F. A. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3323 · Cited by 56
Mina, D. S., Au, D., Brunet, J., Jones, J. M., TOMLINSON, G. A., Taback, N., Field, D., Berlingeri, A., Bradley, H., & Howell, D. (2017) · Current Oncology · doi:10.3747/co.23.3585 · Cited by 55
Promising New Agents for Colorectal Cancer
Das, S., Ciombor, K. K., Haraldsdóttir, S., & Goldberg, R. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0543-z · Cited by 51
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Peng, L.-X., & Wu, Y.-L. L. C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.106 · Cited by 57
Lee, J. J., & Chu, E. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.06.004 · Cited by 55
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 54
Alexander, P. G., McMillan, D., & Park, J. H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103147 · Cited by 54
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 56
Yao, J., Gong, Y., Zhao, W., Han, Z., Guo, S., Liu, H., Peng, X., Xiao, W., Li, Y., Dang, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52414-z · Cited by 53
Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach
Yamamoto, H., Watanabe, Y., Maehata, T., Imai, K., & Itoh, F. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02833-z · Cited by 54
Molina, G. E., Zubiri, L., Cohen, J. V., Durbin, S., Petrillo, L. A., Allen, I. M., Murciano‐Goroff, Y. R., Dougan, M. L., Thomas, M. F., Faje, A. T., et al. (2021) · The Oncologist · doi:10.1002/onco.13740 · Cited by 54
Kuipers, H., de Bitter, T. J. J., de Boer, M. T., van der Post, R. S., Nijkamp, M. W., de Reuver, P. R., Fehrmann, R. S. N., & Hoogwater, F. J. H. (2021) · Cancers · doi:10.3390/cancers13215257 · Cited by 55
Saberzadeh-Ardestani, B., Jones, J. C., Hubbard, J. M., McWilliams, R. R., Halfdanarson, T. R., Shi, Q., Sonbol, M. B., Ticku, J., Jin, Z., & Sinicrope, F. A. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.0400 · Cited by 55
Wu, T., Zhang, X., Liu, X., Cai, X., Shen, T., Pan, D., Liang, R., Ding, R., Hu, R., Dong, J., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02866-y · Cited by 54
Wang, Q., Yu, M., & Zhang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440830 · Cited by 56
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 54
Ahtiainen, M., Wirta, E., Kuopio, T., Seppälä, T. T., Rantala, J., Mecklin, J., & Böhm, J. (2019) · Modern Pathology · doi:10.1038/s41379-019-0219-7 · Cited by 54
Colorectal cancer in adolescents and young adults: Defining a growing threat
Levine, O. H., & Zbuk, K. M. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27941 · Cited by 55
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
Puccini, A., Battaglin, F., Iaia, M. L., Lenz, H., & Salem, M. E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000404 · Cited by 53
Self-citationLin, A., Zhang, H., Hu, X., Chen, X., Wu, G., Luo, P., & Zhang, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105028 · Cited by 55
Emerging treatment options for BRAF-mutant colorectal cancer
Ursem, C. J., Atreya, C. E., & Loon, K. V. (2018) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s125940 · Cited by 54
Kikuchi, T., Mimura, K., Okayama, H., Nakayama, Y., Saito, K., Yamada, L., Endo, E., Sakamoto, W., Fujita, S., Endo, H., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10953 · Cited by 55
Fu, J., Li, W., McGrath, N., Lai, C. W., Brar, G., Xiang, Y., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 53
Kim, C. W., Chon, H. J., & Kim, C. (2021) · Cancers · doi:10.3390/cancers13194906 · Cited by 56
Oh, C. R., Kim, J. E., Hong, Y. S., Kim, S. Y., Ahn, J. B., Baek, J. Y., Lee, M. A., Kang, M. J., Cho, S., Beom, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33966 · Cited by 50
Russo, V., Lallo, E., Munnia, A., Spedicato, M., Messerini, L., D’Aurizio, R., Ceroni, E. G., Brunelli, G., Galvano, A., Russo, A., et al. (2022) · Cancers · doi:10.3390/cancers14164012 · Cited by 52
Akce, M., Farran, B., Switchenko, J. M., Rupji, M., Kang, S., Khalil, L. E., Ruggieri, A. N., Olson, B. M., Shaib, W. L., Wu, C. S.-Y., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007235 · Cited by 55
Immunotherapy of MSI Cancer: Facts and Hopes
Wilbur, H. C., Le, D. T., & Agarwal, P. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1935 · Cited by 54
Lee, Y. S., Song, S. J., Hong, H. K., Oh, B. Y., Lee, W. Y., & Cho, Y. B. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0436-7 · Cited by 52
Yao, L., Jia, G., Lu, L., Bao, Y., & Ma, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106628 · Cited by 54
Şahin, İ. H., & Klostergaard, J. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00160 · Cited by 54
Pietrantonio, F., Loupakis, F., Randon, G., Raimondi, A., Salati, M., Trapani, D., Pagani, F., Depetris, I., Maddalena, G., Morano, F., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0014 · Cited by 51
Self-citationMolecular Pathogenesis and Classification of Colorectal Carcinoma
Kasi, A., Handa, S., Bhatti, S. A., Umar, S., Bansal, A. K., & Sun, W. (2020) · Current Colorectal Cancer Reports · doi:10.1007/s11888-020-00458-z · Cited by 56
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 56
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
Inamori, K., Togashi, Y., Fukuoka, S., Akagi, K., Ogasawara, K., Irie, T., Motooka, D., Kobayashi, Y., Sugiyama, D., Kojima, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.137365 · Cited by 51
Bai, J., Chen, H., & Bai, X. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23810 · Cited by 53
Dasari, A. N., Sobrero, A. F., Yao, J. C., Yoshino, T., Schelman, W. R., Yang, Z., Chien, C., Kania, M. K., Tabernero, J. M., & Eng, C. (2021) · Future Oncology · doi:10.2217/fon-2021-0202 · Cited by 50
Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer
Chen, X., Yang, L., Jin, L., Lin, W., Zhang, F., Huang, S., & Huang, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.962028 · Cited by 52
Li, Y., Du, Y., Xue, C., Wu, P., Du, N., Zhu, G., Xu, H., & Zhi, Z. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02511-7 · Cited by 52
P38 kinase in gastrointestinal cancers
Phan, T. X., Zhang, X. H., Rosen, S. T., & Melstrom, L. G. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00622-1 · Cited by 55
Ros, J., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., Salvà, F., Tabernero, J. M., & Élez, E. (2023) · Cancers · doi:10.3390/cancers15174245 · Cited by 53
Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 66
Batenchuk, C., Albitar, M. X., Zerba, K. E., Sudarsanam, S., Chizhevsky, V., Jin, C., & Burns, V. A. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205362 · Cited by 51
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 52
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Saner, F. A. M., Herschtal, A., Nelson, B. H., DeFazio, A., Goode, E. L., Ramus, S. J., Pandey, A., Beach, J. A., Fereday, S., Berchuck, A., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0145-5 · Cited by 51
Aasebø, K., Dragomir, A., Sundström, M., Mezheyeuski, A., Edqvist, P.-H. D., Eide, G. E., Pontén, F., Pfeiffer, P., Glimelius, B. L. G., & Sørbye, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2205 · Cited by 51
Serrated Colorectal Cancer: The Road Less Travelled?
Nakanishi, Y., Díaz-Meco, M. T., & Moscat, J. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.004 · Cited by 55
Standardized Pathology Report for Colorectal Cancer, 2nd Edition
Kim, B., Kim, J. M., Kang, G. H., Chang, H. J., Kang, D. W., Kim, J. H., Bae, J. M., Seo, A. N., Park, H. S., Kang, Y. K., et al. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.09.28 · Cited by 56
Seyedin, S. N., Hasibuzzaman, M. M., Pham, V., Petronek, M. S., Callaghan, C. M., Kalen, A. L., Mapuskar, K. A., Mott, S. L., Spitz, D. R., Allen, B. G., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.01.030 · Cited by 51
Li, J., Cong, L., Liu, J., Peng, L., Wang, J., Feng, A., Yue, J., Li, L., Wang, X., & Wang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594125 · Cited by 52
Zhang, Y., Zhao, Y., Li, Q., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685978 · Cited by 52
The injury response to DNA damage in live tumor cells promotes antitumor immunity
Sriram, G., Milling, L. E., Chen, J.-K., Kong, Y. W., Joughin, B. A., Abraham, W. D., Swartwout, S., Handly, E. D., Irvine, D. J., & Yaffe, M. B. (2021) · Science Signaling · doi:10.1126/scisignal.abc4764 · Cited by 54
Li, Q., Cheng, X., Zhou, C., Tang, Y., Li, F., Zhang, B., Huang, T., Wang, J., & Tu, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841977 · Cited by 50
FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint
Cappello, F., Angerilli, V., Munari, G., Ceccon, C., Sabbadin, M., Pagni, F., Fusco, N., Malapelle, U., & Fassan, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050750 · Cited by 55
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 54
Patel, R. K., Rahman, S., Schwantes, I. R., Bartlett, A. Q., Eil, R. L., Farsad, K., Fowler, K. J., Goodyear, S. M., Hansen, L., Kardosh, A., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.08.012 · Cited by 55
Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches
Li, F., Lin, Y., Li, R., Shen, X., Xiang, M., Xiong, G., Zhang, K., Xia, T., Guo, J., Miao, Z., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1165666 · Cited by 54
Noda, M., Okayama, H., Tachibana, K., Sakamoto, W., Saito, K., Min, A. K. T., Ashizawa, M., Nakajima, T., Aoto, K., Momma, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3533 · Cited by 51
Hissong, E. M., Crowe, E. P., Yantiss, R. K., & Chen, Y. (2018) · Modern Pathology · doi:10.1038/s41379-018-0094-7 · Cited by 50
Current and Emerging Biomarkers in Metastatic Colorectal Cancer
Lee, M. K. C., & Loree, J. M. (2019) · Current Oncology · doi:10.3747/co.26.5719 · Cited by 50
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma
Almquist, D., Ahn, D. H., & Bekaii‐Saab, T. (2020) · BioDrugs · doi:10.1007/s40259-020-00420-3 · Cited by 50
B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma
Lu, Z., Zhao, Z., Cheng, P., Huang, F., Guan, X., Zhang, M., Chen, H., Liu, Z., Jiang, Z., Zheng, Z., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0587-z · Cited by 49
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Martini, G., Dienstmann, R., Ros, J., Baraibar, I., Cuadra‐Urteaga, J. L., Salvà, F., Ciardiello, D., Mulet-Margalef, N., Argilés, G., Tabernero, J. M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936089 · Cited by 57
Malapelle, U., Parente, P., Pepe, F., Luca, C. D., Cerino, P., Covelli, C., Balestrieri, M., Russo, G., Bonfitto, A., Pisapia, P., et al. (2020) · Cells · doi:10.3390/cells9092019 · Cited by 50
Kleeman, S. O., & Leedham, S. J. (2020) · Cancers · doi:10.3390/cancers12113355 · Cited by 51
Patel, M. R., Falchook, G. S., Hamada, K., Makris, L., & Bendell, J. C. (2021) · Cancer Medicine · doi:10.1002/cam4.3630 · Cited by 48
Xie, Y., Lin, J., Zhang, N., Wang, X., Wang, P., Peng, S., Li, J., Wu, Y., Huang, Y., Zhuang, Z., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7071 · Cited by 49
Taı̈eb, J., Bouché, O., André, T., Malicot, K. L., Laurent‐Puig, P., Bez, J., Toullec, C., Borg, C., Randrian, V., Evesque, L., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2761 · Cited by 49
Self-citationStein, A., & Folprecht, G. (2018) · Oncology Research and Treatment · doi:10.1159/000488918 · Cited by 49
Hazama, S., Tamada, K., Yamaguchi, Y., Kawakami, Y., & Nagano, H. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12180 · Cited by 50
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Wang, Y., & Li, G. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0674-4 · Cited by 49
Koustas, E., Sarantis, P., Kyriakopoulou, G., Papavassiliou, A. G., & Karamouzis, M. V. (2019) · Cancers · doi:10.3390/cancers11040533 · Cited by 50
Salem, M. E., Battaglin, F., Goldberg, R. M., Puccini, A., Shields, A. F., Arguello, D., Korn, W. M., Marshall, J. L., Grothey, A. F., & Lenz, H. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0552 · Cited by 50
Self-citationImmune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index
Pollack, R. M., Ashash, A., Cahn, A., Rottenberg, Y., Stern, H., & Dresner–Pollak, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa458 · Cited by 49
Ren, X., Song, Y. M., Wang, J., Chen, L.-Y., Pang, J., Zhou, L., Shen, S.-J., Cao, X., Wang, Y., Shao, M.-M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.570623 · Cited by 52
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Cohen, R., Liu, H., Fiskum, J., Adams, R., Chibaudel, B., Maughan, T., Cutsem, E. V., Venook, A. P., Douillard, J., Heinemann, V., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab042 · Cited by 48
Self-citationPancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
Taherian, M., Wang, H., & Wang, H. (2022) · Cells · doi:10.3390/cells11193068 · Cited by 52
Progresses in biomarkers for cancer immunotherapy
Lin, X., Zong, C., Zhang, Z., Fang, W., & Xu, P. (2023) · MedComm · doi:10.1002/mco2.387 · Cited by 50
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
Yang, X., Lian, B., Zhang, N., Long, J., Li, Y., Xue, J., Chen, X., Wang, Y., Wang, Y., Xun, Z., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03257-7 · Cited by 49
Liu, D.-X., Li, D., He, W., Ke, C., Wu, J., Tang, J.-H., Kong, L.-H., Li, Y., Sui, Q., Xiao, B.-Y., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1711650 · Cited by 49
van de Donk, P. P., Wind, T. T., Hooiveld-Noeken, J. S., van der Veen, E. L., Glaudemans, A. W. J. M., Diepstra, A., Jalving, M., de Vries, E. G. E., de Vries, E. F. J., & Hospers, G. A. P. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05407-y · Cited by 48
Tan, Z.-L., Yue, C., Ji, S., Zhao, C., Jia, R., Zhang, Y., Liu, R., Li, D., Yu, Q., Li, P., et al. (2021) · The Oncologist · doi:10.1002/onco.13981 · Cited by 49
Metadata
- Authors
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V., Cao, Z. A., Ledeine, J.-M., Maglinte, G. A., Kopetz, S., & André, T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Trials Ireland (IE)
- Allina Health (US)
- Istituto Oncologico Veneto (IT)
- USC Norris Comprehensive Cancer Center (US)
- Duke Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Belgium) (BE)
- Sorbonne Université (FR)
- Corresponding author
- Overman, Michael J
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 18
- Issue
- 9
- Pages
- 1182-1191
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC6207072
- OpenAlex
- W2739132742
- Cited by
- 2,836
- References
- 37
- Citations by year
- 2026: 185 · 2025: 242 · 2024: 302 · 2023: 382 · 2022: 377 · 2021: 438 · 2020: 361 · 2019: 288 · 2018: 223 · 2017: 31
- FWCI
- 108.88
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-01)
- Open access
- green
- europepmc.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (P30CA016672)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- nivolumab, metastatic colorectal cancer, mismatch repair deficiency, microsatellite instability-high, PD-1 inhibitors, immune checkpoint blockade, objective response rate, disease control rate, progression-free survival, overall survival, treatment toxicity, first-line therapy, second-line therapy, third-line therapy, neoantigens, tumor-infiltrating lymphocytes
- MeSH terms
- Nivolumab, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Microsatellite Instability, DNA Mismatch Repair, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
